CME credits: 1.00

Valid until: 01-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-with-triple-class-or-penta-refractory-mm/18054/

"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.